Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats

Abstract

Penile veno-occlusive dysfunction (venogenic erectile dysfunction) is a common cause of erectile dysfunction (ED). We investigated whether vascular endothelial growth factor (VEGF) can be used to prevent and reverse venogenic ED in a rat model. Pharmacological cavernosometry was developed and validated using adult male rats with either arteriogenic or venogenic ED. Castrated animals were treated with intracavernous VEGF as either a recombinant protein (C+VEGF) or adeno-associated virus (AAV)-mediated VEGF gene therapy (C+VEGF gene) in an attempt to prevent the development of venogenic ED. Other animal groups received testosterone replacement (C+testosterone) or intracavernous AAV-LacZ gene (C+LacZ). Animals with documented venogenic ED were treated with intracavernous VEGF in an attempt to reverse their ED. Functional analysis (pharmacological infusion cavernosometry) was performed following treatment. Penile specimens were harvested for immunohistochemistry and electron microscopic evaluation. Castrated rats showed a decrease in papaverine-induced intracavernous pressure and an increase in maintenance and drop rates during pharmacological cavernosometry. These changes were prevented by systemic testosterone and intracavernous VEGF or AAV-VEGF therapy. Moreover, intracavernous VEGF was able to reverse the venogenic ED produced by castration. The quantity of penile smooth muscle detected by alpha actin staining decreased after castration but not in the C+T, C+VEGF, or C+VEGF gene groups. Transmission electron microscopy revealed atrophy of penile smooth muscle cells and nerves in the castrated rats. In VEGF-treated rats, regeneration of smooth muscle and nerves as well as endothelial cell hypertrophy and hyperplasia were the prominent features. In our animal model, systemic testosterone replacement or intracavernous VEGF (protein and VEGF gene) prevented the veno-occlusive dysfunction in castrated animals. In rats with established venous leakage, VEGF treatment reversed the cavernosometric findings of leakage. Intracavernous injection of either VEGF protein or VEGF gene may be a preferred therapy to preserve erectile function in patients in whom testosterone therapy is contraindicated.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3

References

  1. Lue TF . Contemporary Diagnosis and Management of Male Erectile Dysfunction. Handbooks in Health Care Co.: Newtown, Penn., 1999.

    Google Scholar 

  2. Karadeniz T et al. Judgment of color Doppler ultrasound with respect to cavernous artery occlusion pressure in dynamic infusion cavernosometry when evaluating arteriogenic impotence. Urol Int 1996; 57: 85–88.

    Article  CAS  Google Scholar 

  3. Mulhall JP, Graydon RJ . The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Int J Impot Res 1996; 8: 91–94.

    CAS  PubMed  Google Scholar 

  4. Mersdorf A et al. Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J Urol 1991; 145: 749–758.

    Article  CAS  Google Scholar 

  5. Rajfer J, Rosciszewski A, Mehringer M . Prevalence of corporeal venous leakage in impotent men. J Urol 1988; 140: 69–71.

    Article  CAS  Google Scholar 

  6. Meisel RL, O'Hanlon JK, Sachs BD . Differential maintenance of penile responses and copulatory behavior by gonadal hormones in castrated male rats. Horm Behav 1984; 18: 56–64.

    Article  CAS  Google Scholar 

  7. Zvara P et al. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res 1995; 7: 209–219.

    CAS  PubMed  Google Scholar 

  8. Lekås E et al. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25: 309–314.

    Article  Google Scholar 

  9. Häggström S, Wikström P, Bergh A, Damber JE . Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998; 36: 71–79.

    Article  Google Scholar 

  10. Mills TM, Lewis RW, Stopper VS . Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol Reprod 1998; 59: 1413–1418.

    Article  CAS  Google Scholar 

  11. Mills TM, Stopper VS, Wiedmeier VT . Effects of castration and androgen replacement on the hemodynamics of penile erection in the rat. Biol Reprod 1994; 51: 234–238.

    Article  CAS  Google Scholar 

  12. Franck-Lissbrant I, Häggström S, Damber JE, Bergh A . Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats [see comments]. Endocrinology 1998; 139: 451–456.

    Article  CAS  Google Scholar 

  13. Häggström S, Lissbrant IF, Bergh A, Damber JE . Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620–1625.

    Article  Google Scholar 

  14. Liu X et al. Vascular endothelial growth factor promotes proliferation and migration of cavernous smooth muscle cells. J Urol 2001; 166: 354–360.

    Article  CAS  Google Scholar 

  15. Jin KL, Mao XO, Greenberg DA . Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000; 97: 10242–10247.

    Article  CAS  Google Scholar 

  16. Sondell M, Sundler F, Kanje M . Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243–4254.

    Article  CAS  Google Scholar 

  17. Verdonck A et al. Effect of testosterone replacement after neonatal castration on craniofacial growth in rats. Arch Oral Biol 1998; 43: 551–557.

    Article  CAS  Google Scholar 

  18. Parker CR Jr, Ellegood JO, Mahesh VB . Methods for multiple steroid radioimmunoassay. J Steroid Biochem 1975; 6: 1–8.

    Article  CAS  Google Scholar 

  19. Su H, Lu R, Kan YW . Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA 2000; 97: 13801–13806.

    Article  CAS  Google Scholar 

  20. Karadeniz T et al. Correlation of ultrastructural alterations in cavernous tissue with the clinical diagnosis vasculogenic impotence. Urol Int 1996; 57: 58–61.

    Article  CAS  Google Scholar 

  21. Baumgartner I et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [see comments]. Circulation 1998; 97: 1114–1123.

    Article  CAS  Google Scholar 

  22. Symes JF et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830–836; discussion 836–837.

    Article  CAS  Google Scholar 

  23. Henry GD et al. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Int J Impot Res 2000; 12: 334–339.

    Article  CAS  Google Scholar 

  24. Byrne RR et al. Vascular endothelial growth factor restores corporeal smooth muscle function in vitro. J Urol 2001; 165: 1310–1315.

    Article  CAS  Google Scholar 

  25. Lee MC et al. The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. J Urol 2002; 167: 761–767.

    Article  CAS  Google Scholar 

  26. Mills TM, Dai Y, Stopper VS, Lewis RW . Androgenic maintenance of the erectile response in the rat. Steroids 1999; 64: 605–609.

    Article  CAS  Google Scholar 

  27. Hatzichristou DG et al. In vivo Assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernous pressure determinants [see comments]. J Urol 1995; 153: 1126–1135.

    Article  CAS  Google Scholar 

  28. Karadeniz T et al. Value of color Doppler sonography in the diagnosis of venous impotence. Urol Int 1995; 55: 143–146.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported in part by a grant from the National Institute of Health (NIH-DK51374).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T F Lue.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rogers, R., Graziottin, T., Lin, CS. et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res 15, 26–37 (2003). https://doi.org/10.1038/sj.ijir.3900943

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900943

Keywords

  • erectile dysfunction
  • cavernosometry
  • vascular endothelial growth factor
  • gene therapy
  • castration

This article is cited by

Search

Quick links